A Randomized, Phase II Trial of Brief Androgen-Ablation Combined With Cell-based CG1940/CG8711 Immunotherapy For Prostate Cancer in Patients With Non-Metastatic, Biochemically Relapsed Prostate Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 18 May 2018
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Tumour cell vaccine-GVAX
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Aug 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Oct 2008 New trial record.